EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Remibrutinib in Chronic Spontaneous Urticaria

Martin Metz iD, Ana Giménez-Arnau, Michihiro Hide, Mark Lebwohl, Giselle Mosnaim, Sarbjit Saini, Gordon Sussman, Robert Szalewski, Sibylle Haemmerle, Karine Lheritier, El-Djouher Martzloff, Noriko Seko und 6 weitere

New England Journal of Medicine · 06.03.2025 · 392 (10) · 984-994

DOI: 10.1056/nejmoa2408792 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 06.03.2025. Verfasst von Martin Metz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Urticaria Center of Reference and Excellence, Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Ber…. Hauptthemen laut MEDLINE: Chronic Urticaria, Pruritus, Pyrimidines, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaPruritusPyrimidinesTyrosine Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedAdministration, OralAgammaglobulinaemia Tyrosine KinaseDouble-Blind MethodSeverity of Illness IndexTreatment Outcome

Substanzen

Agammaglobulinaemia Tyrosine KinasePyrimidinesremibrutinibTyrosine Kinase InhibitorsBTK protein, human

Autor:innen und Institutionen

  • Urticaria Center of Reference and Excellence, Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin.
  • Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin.
  • Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona.
  • Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Dermatology, Hiroshima University, Hiroshima, Japan.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.

ORCID-Profile: Martin Metz

Zitieren

APA

Metz, M., Giménez-Arnau, A., Hide, M., Lebwohl, M., Mosnaim, G., Saini, S., Sussman, G., Szalewski, R., Haemmerle, S., Lheritier, K., Martzloff, E. D., Seko, N., Wang, P., Zharkov, A., Maurer, M., REMIX-1 and REMIX-2 Investigators, REMIX-1 Investigators, & REMIX-2 Investigators (2025). Remibrutinib in Chronic Spontaneous Urticaria. New England Journal of Medicine, 392(10), 984-994. https://doi.org/10.1056/nejmoa2408792

Vancouver

Metz M, Giménez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, et al. Remibrutinib in Chronic Spontaneous Urticaria. New England Journal of Medicine. 2025;392(10):984-994. doi:10.1056/nejmoa2408792

BibTeX
@article{Metz2025,
  author = {Metz, Martin and Giménez-Arnau, Ana and Hide, Michihiro and Lebwohl, Mark and Mosnaim, Giselle and Saini, Sarbjit and Sussman, Gordon and Szalewski, Robert and Haemmerle, Sibylle and Lheritier, Karine and Martzloff, El-Djouher and Seko, Noriko and Wang, Pengpeng and Zharkov, Artem and Maurer, Marcus and REMIX-1 and REMIX-2 Investigators, REMIX-1 and REMIX-2 Investigators and REMIX-1 Investigators, REMIX-1 Investigators and REMIX-2 Investigators, REMIX-2 Investigators},
  title = {Remibrutinib in Chronic Spontaneous Urticaria},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {10},
  pages = {984--994},
  doi = {10.1056/nejmoa2408792}
}
Kostenlos starten →